Revolutionizing Healthcare: Introducing AI Voice Agents
Soaring Demand across Healthcare: Use Cases and Industry Adoption
Healthcare organizations—both providers and payers—are increasingly turning to AI voice agents to relieve administrative burdens, enhance patient engagement, and reduce costs. Deployments are concentrated across:
· Appointment scheduling & patient engagement: Voice agents field inbound calls 24/7, eliminating missed appointments and reducing staff workloads.
· Clinical documentation: Ambient and interactive AI agents capture encounter details in real time.
· Patient triage & symptom checking: Offering preliminary guidance and care navigation.
· Billing & insurance communication: Answering cost inquiries, verifying benefits, and guiding claim workflows.
· Mental‑health support & companionship bots: Supporting vulnerable populations with empathetic conversational AI.
Recent study indicate that over 85 % of implementations are cloud‑based, and hospitals & health‑systems currently lead adoption. However, independent clinics are rapidly embracing conversational tools, with adoption expected to accelerate during the forecast period.
Real‑World Deployments: Product launch & Use Cases
Zocdoc – 'Zo' (May 2025)
Zocdoc launched 'Zo,' an AI phone assistant, in May 2025. Scheduled to address the bottleneck of hold times, Zo answers inbound scheduling calls on the first ring—24/7—handling unlimited volume and integrating seamlessly with practice EHRs. In early deployments, Zo resolves up to 70 % of calls within an average 3½ minutes, yielding an 83 % patient satisfaction rating. Providers like SINY Dermatology, Schweiger Dermatology Group, and QualDerm Partners have implemented Zo to manage peak call volumes efficiently.
eHealth, Inc.
In April 2025, eHealth, Inc. introduced an AI-driven voice assistant to guide consumers through health insurance plan selection. Acting as a non‑licensed agent, it enhances licensed agents' capabilities with an empathetic, conversational interface built into eHealth's service ecosystem.
Innovaccer Inc. – Agents of Care™ (February 2025)
At its Xccelerate 2025 conference, Innovaccer launched 'Agents of Care™,' pre‑trained AI agents built to automate repetitive care management and documentation tasks in response to staffing shortages. These agents helped reduce documentation time by 28 % and boosted patient engagement by 20 %.
Cedar – 'Kora' (April 2025)
Cedar debuted 'Kora' in late April 2025 as a voice agent designed to answer billing and payment calls. Pilot users—like ApolloMD—have found that Kora naturally handles patient inquiries about deductibles and costs, letting financial staff focus on complex cases
Infinitus & Cencora
Cencora has enhanced its patient access program by integrating Infinitus, which streamlines operations and improves patient care access. This collaboration involved incorporating Infinitus voice AI agents into Cencora's proprietary benefit verification system. The advanced technology within Cencora's ecosystem facilitates a more efficient process for benefit verification, reverification, prior authorization, and reporting, ultimately saving staff time and resources.
Lumeris – 'Tom' for Post‑Discharge Care
In February 2025, Lumeris, unveiled Tom, the most sophisticated AI-driven Primary Care as a Service solution aimed at alleviating the burdens faced by physicians and their teams while enhancing patient access to care. Tom functions as an AI-integrated member of the care team, seamlessly incorporated into clinical workflows to proactively expand the primary care team's capabilities in essential areas such as prevention and wellness, care coordination, social determinants of health, population health, and chronic disease management.
Regional adoption trends:
The adoption of AI voice agents in healthcare is gaining momentum globally, with North America leading the charge due to its advanced healthcare infrastructure, high investment in digital health, and presence of major AI vendors. The United States, in particular, has seen rapid integration of voice agents across hospitals, outpatient clinics, and insurance providers, largely to alleviate administrative burdens and improve patient access. This region benefits from supportive regulatory frameworks, reimbursement incentives, and a growing need to combat staffing shortages.
Europe follows closely, with countries like Germany, the UK, and France accelerating adoption through national AI strategies, robust data protection regulations, and increased funding for healthcare innovation. European healthcare systems are embracing voice AI to streamline operations while ensuring compliance with privacy laws such as GDPR.
Meanwhile, the Asia-Pacific region is experiencing the fastest growth in AI voice agent adoption, driven by rising healthcare demand, increasing public-private investments, and large, multilingual populations. Countries like China, Japan, and India are deploying these technologies to improve access in underserved areas and reduce strain on overburdened systems.
Latin America and the Middle East & Africa are at earlier stages of adoption but are progressing steadily, supported by government-led digital health initiatives and collaborations with global tech firms. As infrastructure matures and awareness of AI's benefits increases, these emerging regions are poised to become significant contributors to the global AI voice agents market.
Merger & Acquisition Activity:
Acquisitions are creating synergies: core strengths in conversational AI are paired with domain expertise in payer communication, billing compliance, clinical workflows, and patient experiences—positioning these companies to scale rapidly.
In August 2024, SoundHound AI, Inc., a global leader in voice artificial intelligence, announced its acquisition of Amelia, a prominent enterprise AI software company. This strategic merger positions SoundHound AI as the leading provider of voice and conversational generative AI, extending its influence across various sectors, including retail, financial services, healthcare, automotive, smart devices, and restaurants, among others.
In January 2025, SuperDial completed the acquisition of MajorBoost, a prominent conversational AI firm that focuses on automating phone interactions with health insurers. This strategic move significantly bolsters SuperDial's voice AI capabilities, paving the way for enhanced operational efficiencies within healthcare organizations.
As the healthcare industry continues to evolve, AI voice agents are proving to be a pivotal force in reshaping patient interactions, operational efficiency, and overall care delivery. From automating routine administrative tasks to enhancing patient engagement and access, these intelligent systems are driving measurable improvements across the care continuum. With strong adoption in mature markets and accelerating interest in emerging regions, the future of AI voice technology in healthcare looks exceptionally promising. As innovation continues and more healthcare stakeholders embrace digital transformation, AI voice agents will play an increasingly central role in delivering scalable, personalized, and efficient healthcare experiences worldwide.
About Author:
HTF Market Intelligence Consulting is uniquely positioned to empower and inspire with research and consulting services to empower businesses with growth strategies, by offering services with extraordinary depth and breadth of thought leadership, research, tools, events, and experience that assist in decision-making.
TIME BUSINESS NEWS
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
Macy's, Inc. Announces Pricing of Senior Notes
NEW YORK--(BUSINESS WIRE)--Macy's, Inc. (NYSE: M) (the 'Company') announced today that its wholly-owned subsidiary, Macy's Retail Holdings, LLC (the 'Issuer'), priced an offering of $500 million in aggregate principal amount of 7.375% senior notes due 2033 (the 'Notes') in a private offering at an offering price of 100% of the principal amount thereof. The Notes will have a maturity date of August 1, 2033. The closing of the offering of the Notes is expected to occur on July 29, 2025, subject to customary closing conditions. The Notes will be senior unsecured obligations of the Issuer and will be unconditionally guaranteed on a senior unsecured basis by the Company. The Issuer intends to use the proceeds from the offering of the Notes, together with cash on hand, to (i) fund its separately announced concurrent tender offer (the 'Tender Offer'), (ii) redeem approximately $587 million of certain of its existing outstanding senior notes and debentures (such redemption, the 'Redemption') and (iii) pay fees, premium and expenses in connection therewith and this offering. The Redemption and the Tender Offer are conditioned on, among other things, the consummation of the offering of the Notes. The offering of the Notes, however, is not conditioned on the consummation of the Redemption or the Tender Offer (including the tender of any specified amount of the Company's outstanding senior notes as part of the Tender Offer). This press release does not constitute an offer to purchase, a solicitation of an offer to sell or a notice with respect to any tender offer or redemption of any existing notes. This press release is for informational purposes only and is neither an offer to sell nor the solicitation of an offer to buy the Notes or any other securities and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offering, solicitation or sale would be unlawful. Any offers of the Notes will be made only by means of a private offering memorandum. The Notes are being offered only to persons reasonably believed to be qualified institutional buyers in an offering exempt from registration in reliance on Rule 144A under the Securities Act of 1933, as amended (the 'Securities Act'), and outside the United States in reliance on Regulation S under the Securities Act. The Notes and related guarantees have not been registered under the Securities Act or any state securities laws and may not be offered or sold in the United States without registration or an applicable exemption from the registration requirements of the Securities Act or any applicable state securities laws. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act. About Macy's, Inc. Macy's, Inc. (NYSE: M) is a trusted source for quality brands through our iconic nameplates – Macy's, Bloomingdale's and Bluemercury. Headquartered in New York City, our comprehensive digital and nationwide footprint empowers us to deliver a seamless shopping experience for our customers. Forward-Looking Statements All statements in this press release regarding the closing of the notes offering and the expected use of proceeds therefrom that are not statements of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties. Actual results could differ materially from those expressed in or implied by the forward-looking statements contained in this release because of a variety of factors, including, but not limited to, general market conditions which might affect the offering, and other factors identified in documents filed by the Company with the Securities and Exchange Commission, including under the captions 'Forward-Looking Statements' and 'Risk Factors' in the Company's Annual Report on Form 10-K for the year ended February 1, 2025 and the Company's Quarterly Report on Form 10-Q for the quarterly period ended May 3, 2025. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Business Wire
3 hours ago
- Business Wire
Teradyne to Announce Second Quarter 2025 Results
NORTH READING, Mass.--(BUSINESS WIRE)-- Teradyne, Inc. (NASDAQ: TER) will release financial results for the second quarter 2025 on Tuesday, July 29 at 5:00 p.m. Eastern Time (ET) or later. A conference call to discuss the second quarter results, along with management's business outlook, will follow at 8:30 a.m. ET, Wednesday, July 30, 2025. Interested investors should access the webcast at at least five minutes before the call begins. Presentation materials will be available starting at 7:30 a.m. ET. A replay will be available on the Teradyne website at About Teradyne Teradyne (NASDAQ:TER) designs, develops, and manufactures automated test equipment and advanced robotics systems. Its test solutions for semiconductors and electronics products enable Teradyne's customers to consistently deliver on their quality standards. Its advanced robotics business includes collaborative robots and mobile robots that support manufacturing and warehouse operations for companies of all sizes. For more information, visit Teradyne® is a registered trademark of Teradyne, Inc., in the U.S. and other countries.
Business Wire
3 hours ago
- Business Wire
Hamilton ETFs Launches the DayMAX™ ETFs, Canada's First 0DTE ETFs
TORONTO--(BUSINESS WIRE)--Hamilton Capital Partners Inc. (" Hamilton ETFs") is pleased to announce the launch of its suite of DayMAX™ ETFs: Hamilton Enhanced Canadian Equity DayMAX™ ETF (' CDAY '), Hamilton Enhanced U.S. Equity DayMAX™ ETF (' SDAY '), and Hamilton Enhanced Technology DayMAX™ ETF (' QDAY '; together, the ' DayMAX™ ETFs '). The DayMAX™ lineup – CDAY, SDAY, and QDAY – is purpose-built for income-focused investors, providing a new way to generate higher and more frequent cash flow across Canadian equities, U.S. equities, and Technology, respectively. Share ETF Name Ticker Units Investment Objective Hamilton Enhanced Canadian Equity DayMAX™ ETF CDAY Class E Units To deliver attractive income while providing exposure primarily, but not exclusively, to Canadian equities. To supplement income earned from its holdings, CDAY employs an actively managed, primarily ultra-short-term, option strategy on its North American equity exposure and employs modest 25% leverage. Hamilton Enhanced U.S. Equity DayMAX™ ETF SDAY Class E Units To deliver attractive income while providing exposure primarily to U.S. equities. To supplement income earned from its holdings, SDAY employs an actively managed, primarily ultra-short-term, option strategy and employs modest 25% leverage. Hamilton Enhanced Technology DayMAX™ ETF QDAY Class E Units To deliver attractive income while providing exposure primarily to U.S. technology-focused equities. To supplement income earned from its holdings, QDAY employs an actively managed, primarily ultra-short-term, option strategy and employs modest 25% leverage. Expand The DayMAX™ ETFs have closed the offering of their initial Class E units. Units of the DayMAX™ ETFs will begin trading on Tuesday, July 15, 2025, on Cboe Canada Inc. (' Cboe Canada '), under the ticker symbols: 'CDAY', 'SDAY', and 'QDAY'. 'We're proud to launch Canada's first suite of ETFs using 0DTE (zero days to expiry) options with our DayMAX™ ETFs. The DayMAX™ lineup – CDAY, SDAY, and QDAY – is purpose-built for income-focused investors, providing a new way to generate higher and more frequent cash flow across Canadian equities, U.S. equities, and Technology, respectively. By writing daily call options and employing modest 25% leverage, the DayMAX™ ETFs aim to deliver attractive premium income, broad equity exposure, and the potential to benefit from overnight market gains,' said Pat Sommerville, Co-CEO at Hamilton ETFs. For more information on the DayMAX™ ETFs, and the rest of Hamilton ETFs' innovative suite of ETFs, please visit About Hamilton Capital Partners Inc. (Hamilton ETFs) With over $8 billion in assets under management, Hamilton ETFs is one of Canada's fastest-growing ETF providers, offering a suite of innovative exchange traded funds (ETFs) designed to maximize income and growth from trusted sectors in Canada and across the globe. The firm is also an active commentator on the global financial services sector and Canadian banks; the firm's most recent Insights can be found at Commissions, management fees and expenses all may be associated with an investment in exchange traded funds (ETFs). Please read the prospectus before investing. ETFs are not guaranteed, their values change frequently and past performance may not be repeated. Certain statements contained in this news release constitute forward-looking information within the meaning of Canadian securities laws. Forward-looking information may relate to a future outlook and anticipated distributions, events or results and may include statements regarding future financial performance. In some cases, forward-looking information can be identified by terms such as "may", "will", "should", "expect", "anticipate", "believe", "intend" or other similar expressions concerning matters that are not historical facts. Actual results may vary from such forward-looking information. Hamilton ETFs undertakes no obligation to update publicly or otherwise revise any forward-looking statement whether as a result of new information, future events or other such factors which affect this information, except as required by law.
